Vera Therapeutics, Inc.
VERA
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B
$35.89
▲ +2.57%
P/E
-6.12
Mkt Cap
$2.6B
52-Wk Range
$22.72–$56.05
52-Week Range
$22.72 - $56.05
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 45.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class or best-in-class potential for atacicept in IgAN treatment
- Subcutaneous self-administration route improving patient convenience
- Focused pipeline targeting high-unmet-need immunological diseases
- Experienced management team in immunology and gene therapy
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Positive Phase IIb clinical trial data for atacicept could drive regulatory approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+13.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VERA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 10, 2026
Reported EPS of -$1.52 vs -$1.58 consensus (+3.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
10%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 12, 2026
vs Industry
How VERA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related